A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

← catalyst calendar

NCT07744126 · readout ≤ 1,169 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

150estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-09-30

estimated

When the study began enrolling

Primary completion

Oct 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2029

estimated

The whole study's end, after follow-up

First posted

2026-08-04

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Head and Neck Squamous Cell Carcinoma

Interventions

Drug: Telisotuzumab Adizutecan
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Fluorouracil

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants with Adverse Events (AE)s

measured Up to Approximately 38 Months

Objective Response (OR) Rate Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1

measured Up to Approximately 38 Months

Progression-Free Survival (PFS) Based on Blinded Independent Central Review Assessment per Response Evaluation Criteria in Solid Tumors Version 1.1

measured Up to Approximately 38 Months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed